v3.26.1
Collaboration and License Agreements (Tables)
 9 Months Ended
Jun. 30, 2026
Collaboration And License Agreements [Abstract]  
Schedule of Revenue
The following table provides a summary of revenue recognized from our collaboration and license agreements:
Three Months Ended June 30,Nine Months Ended June 30,
2026202520262025
(in thousands)
GSK$— $143 $— $2,646 
Sarepta26,395 27,624 297,594 570,330 
Novartis20,232 — 74,945 — 
Sanofi1,241 — 11,983 — 
Madrigal25,000 — 25,000 — 
Total$72,868 $27,767 $409,522 $572,976 
Schedule of Receivables and Contract Liabilities
The following table summarizes the balance of receivables, contract assets and contract liabilities related to the Company’s collaboration and license agreements, which, as of June 30, 2026, relate solely to the Company’s agreements with Sarepta, Novartis and Sanofi:
June 30, 2026September 30, 2025
(in thousands)
Receivables included in accounts receivable$5,799 $6,824 
Contract assets included in other current assets
$10,231 $— 
Contract liabilities included in deferred revenue, current$94,596 $2,399 
Contract liabilities included in deferred revenue, non-current
$31,743 $— 
Deferred revenue consisted of the following:
Three Months Ended June 30,Nine Months Ended June 30,
2026202520262025
(in thousands)
Balance at beginning of period
$157,159 $43,268 $2,399 $— 
Deferred revenue additions
545 7,335 481,217 593,309 
Revenue recognized
(46,627)(27,624)(372,539)(570,330)
Balance at end of period
111,077 22,979 111,077 22,979 
Plus receivables included in accounts receivable; and contract assets included in other current assets15,262 — 15,262 — 
Less deferred revenue, current
(94,596)(22,979)(94,596)(22,979)
Deferred revenue, non-current
$31,743 $— $31,743 $—